ClinicaliQ Trial Snapshot
- A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors — Recruiting • Phase II • Oncology • NCT06157892.
- What is being tested: Disitamab vedotin, a novel antibody-drug conjugate, is being evaluated in combination with other anticancer agents to determine efficacy and safety across various solid tumour types.
- Patient eligibility overview: The trial enrolls adults with histologically confirmed solid tumours (such as lung or liver cancers) that have either progressed locally or metastasised; specific eligibility criteria depend on tumour type and prior treatment history.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment…
Eligibility Snapshot
- : General Inclusion Criteria * Measurable disease according to RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 Dose Escalation and Optimization Phase Inclusion Criteria * Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma or breast carcinoma * Locally-advanced, unresectable, or metastatic stage * Must have experienced disease progression on or after standard of care therapies or be intolerant of standard of care therapies. Cohort A (HER2-Low Breast Cancer) Inclusion Criteria * Histologically or cytologically confirmed diagnosis of breast carcinoma * Locally-advanced, unresectable, or metastatic stage * HER2-low status determined by most recent local assessment (IHC 1+ or IHC 2+/ISH-negative) * Prior therapies requirements * No more than 3 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mBC. * Participants with known BRCA mutation must have received a PARP-inhibitor where available and not medically contraindicated * Have progression on or after, or intolerant to, T-DXd, sacituzumab govitecan, or other topoisomerase I inhibitor therapies, if available as local standard of care therapy * Participants with HR+ tumors must have intolerance to endocrine therapy or endocrine therapy refractory disease: * Progressed on ≥2 lines of endocrine therapy for LA/mBC AND had received…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.